Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Top Cited Papers
- 21 September 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in CardioVascular and Interventional Radiology
- Vol. 39 (3), 334-343
- https://doi.org/10.1007/s00270-015-1208-y
Abstract
Transarterial chemoembolization with Lipiodol (Lipiodol TACE), also called conventional TACE, was developed in the early 1980s and widely adopted worldwide after randomized control trials and meta-analysis demonstrated superiority of Lipiodol TACE to best supportive care. Presently, there is no level one evidence that other TACE techniques are superior to Lipiodol TACE for intermediate stage hepatocellular carcinoma (HCC), which includes patients with preserved liver function and nonsurgical large or multinodular HCC without distant metastases. In addition, TACE is part of the treatment for progressive or symptomatic liver metastases from gastroenteropancreatic neuroendocrine tumors. When injected into the hepatic artery, Lipiodol has the unique property of selective uptake and retention in hyperarterialyzed liver tumors. Lipiodol/drug emulsion followed by particle embolization has been demonstrated to improve the pharmacokinetic of the drug and tumor response. Radio opacity of Lipiodol helps to monitor treatment delivery, with retention of Lipiodol serving as an imaging biomarker for tumor response. For 30 years, Lipiodol TACE has been inconsistently referenced in many publications with various levels of details for the method of preparation and administration, with reported progressive outcomes following improvements in the technique and the devices used to deliver the treatment and better patient selection. Consequently, there is no consensus on the standard method of TACE regarding the use of anticancer agents, embolic material, technical details, and the treatment schedule. In order to develop an internationally validated technical recommendation to standardize the Lipiodol TACE procedure, a worldwide panel of experts participated in a consensus meeting held on May 10, 2014 .Keywords
This publication has 82 references indexed in Scilit:
- Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular CarcinomaGastroenterology, 2014
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal of Cancer, 2012
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaJournal of Hepatology, 2002
- Rising Incidence of Hepatocellular Carcinoma in the United StatesThe New England Journal of Medicine, 1999
- Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization.Radiology, 1993
- Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinomaCardioVascular and Interventional Radiology, 1990
- Transcatheter oily chemoembolization of hepatocellular carcinoma.Radiology, 1989
- Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary reportEuropean Journal of Cancer and Clinical Oncology, 1983
- Hepatic artery embolization in 120 patients with unresectable hepatoma.Radiology, 1983